LY-320,135
| File:LY-320,135.png | |
| Systematic (IUPAC) name | |
|---|---|
|
4-[6-methoxy-2-(4-methoxyphenyl)1-benzofuran-3-carbonyl]benzonitrile
|
|
| Identifiers | |
| CAS Number | 176977-56-3 |
| PubChem | CID: 5311257 |
| IUPHAR/BPS | 742 |
| Chemical data | |
| Formula | C24H17NO4 |
| Molecular mass | 383.395 |
|
|
| (verify) | |
LY-320,135 is a drug used in scientific research which acts as a selective antagonist of the cannabinoid receptor CB1. It was developed by Eli Lilly and Company in the 1990s.
LY-320,135 displays fairly good selectivity, with a binding affinity for CB1 around 70x stronger than for CB2,[1] but both its potency and selectivity are modest compared to newer agents, and at higher doses it also binds to a range of non-cannabinoid receptors. However LY-320,135 is still fairly widely used in research, particularly for elucidating the mechanisms by which many CB1 antagonists act as inverse agonists at higher doses.[2]
References
- ↑ Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ, Cullinan GJ, Hunden DC, Johnson DW, Chaney MO, Koppel GA, Brownstein M. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. Journal of Pharmacology and Experimental Therapeutics. 1998 Jan;284(1):291-7. PMID 9435190
- ↑ Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sciences. 2005 Feb 4;76(12):1307-24. PMID 15670612
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
- Pages with broken file links
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugboxes with an unspecified ATC code
- Drugs with no legal status
- Cannabinoids
- CB1 receptor antagonists
- Benzofurans
- Phenol ethers
- Ketones
- Nitriles
- Eli Lilly and Company
- Cannabinoid stubs
